Mersana Therapeutics Inc
NASDAQ:MRSN

Watchlist Manager
Mersana Therapeutics Inc Logo
Mersana Therapeutics Inc
NASDAQ:MRSN
Watchlist
Price: 29.08 USD 0.14% Market Closed
Market Cap: 145.4m USD

Wall Street
Price Targets

MRSN Price Targets Summary
Mersana Therapeutics Inc

Wall Street analysts forecast MRSN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRSN is 51 USD with a low forecast of 50.5 USD and a high forecast of 52.5 USD.

Lowest
Price Target
50.5 USD
74% Upside
Average
Price Target
51 USD
75% Upside
Highest
Price Target
52.5 USD
81% Upside
Mersana Therapeutics Inc Competitors:
Price Targets
688687
Beijing Kawin Technology Share-holding Co Ltd
80% Upside
9966
Alphamab Oncology
14% Upside
PHM
Pharma Mar SA
23% Upside
EVAX
Evaxion Biotech A/S
176% Upside
ONCO
Oncopeptides AB
53% Upside
SPRB
Spruce Biosciences Inc
220% Upside
TNG
Transgene SA
57% Upside
UTHR
United Therapeutics Corp
16% Upside

Revenue
Forecast

Revenue Estimate
Mersana Therapeutics Inc

For the last 8 years the compound annual growth rate for Mersana Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 11%.

6%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mersana Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Mersana Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MRSN's stock price target?
Price Target
51 USD

According to Wall Street analysts, the average 1-year price target for MRSN is 51 USD with a low forecast of 50.5 USD and a high forecast of 52.5 USD.

What is Mersana Therapeutics Inc's Revenue forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Mersana Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 11%.

Back to Top